2 completed, 2 terminated, 1 not yet recruiting, 1 unknown. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Terminated 2, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 3 | Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow Skull Neoplasms: new trials by email Literature Review of Skull Neoplasms trials Research Report on Skull Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-11-30 | 2026-11-03 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial 5-Aminolevulinic acid Hydrochloride - Neoplasm, Skull Base Neoplasm | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2021-09-14 | 2025-07-28 |
| Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction EB-CMF - Mandible Tumor, Mandibular Injuries | Phase 1 / Phase 2 | Unknown | Epibone, Inc. | 6 | 2021-03-31 | 2022-05-27 |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Tabelecleucel, Pembrolizumab - Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms | Phase 1 / Phase 2 | Terminated | Atara Biotherapeutics | 12 | 2019-02-19 | 2024-11-14 |
| Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Cetuximab, Hydroxyurea, Fluorouracil - Head and Neck Cancer, Cancer of the Pharynx | Phase 2 | Completed | Johnny Kao | 33 | 2007-02-01 | 2018-03-13 |
Head and Neck Neoplasms (4) · Nose Neoplasms (3) · Laryngeal Neoplasms (2) · Neoplasms (2) · Pharyngeal Neoplasms (2) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Congenital Abnormalities (1) · Epstein-Barr Virus Infections (1) · Esthesioneuroblastoma, Olfactory (1) · Hypopharyngeal Neoplasms (1) · Jaw Neoplasms (1) · Lip Neoplasms (1) · Mandibular Injuries (1) · Mandibular Neoplasms (1)
Bone Diseases (6) · Bone Neoplasms (6) · Musculoskeletal Diseases (6) · Neoplasms by Site (5) · Neoplasms (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Nose Diseases (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Stomatognathic Diseases (3) · Jaw Diseases (2) · Laryngeal Diseases (2) · Neoplasms by Histologic Type (2)
pembrolizumab (2) · Aminolevulinic Acid (1) · Cetuximab (1) · Electrocardiography (1) · Fluorouracil (1) · Hydroxyurea (1) · Ibuprofen (1) · Positron-Emission Tomography (1) · Radionuclide Imaging (1) · Radiotherapy (1) · Tomography, X-Ray Computed (1)
Atara Biotherapeutics (1) · Epibone, Inc. (1) · Icahn School of Medicine at Mount Sinai (1) · Johnny Kao (1) · National Cancer Institute (NCI) (1) · Washington University School of Medicine (1)
United States (6)
Aditi Mehta, DO (1) · Alfred-Marc Iloreta, MD (1) · Brian R Gastman, MD (1) · Charalampos Floudas, M.D. (1) · Johnny Kao, MD (1) · Sana Karam, MD, PhD (1) · Sidharth Puram, MD, PhD (1)